No Young Woman Has Died from Cervical Cancer in the UK for Years: A Positive Trend

From 2020 to 2024, the UK recorded zero deaths from cervical cancer among women aged 20 to 24, marking a historic milestone attributed to the widespread implementation of the human papillomavirus (HPV) vaccine.

“The results are staggering,” states Peter Sasieni from Queen Mary University of London. “It is tragic when cervical cancer claims the life of someone so young. The rapid rollout of the vaccine is a monumental achievement for vaccination efforts, scientific advancements, and public health.”

HPV is a sexually transmitted virus responsible for altering cells in ways that significantly increase the likelihood of cancer development. Consequently, women can face cervical cancer as early as their 20s, and tragically, many still lose their lives to this disease globally.

Initially made available in 2006, the HPV vaccine has been administered to girls aged 12 and 13 in the UK since 2008. As of 2019, boys are also being vaccinated against HPV to prevent additional cancers caused by the virus, such as those affecting the mouth, throat, and anus, while also curbing transmission.

This groundbreaking study reveals that the HPV vaccine not only substantially reduces HPV infections but also curtails cervical cancer-related fatalities. Research on cervical cancer incidence has indicated that the vaccine’s impact extends beyond what was previously assumed. Concerns arose that vaccination primarily benefited women who regularly attend screenings, but findings now show protections extend to those missing out on critical screening opportunities, highlighting the vaccine’s lifesaving potential.

Fortunately, this concern appears unfounded. Sasieni and his team, including Milena Falcaro, have been closely monitoring cervical cancer rates and fatalities in the UK. They found no deaths among those aged 20-24 from 2020 to 2024, a significant drop from the estimated 23 expected fatalities based on historical data. “In my experience, there has never been a year recorded with zero deaths. Therefore, five consecutive years without fatalities is remarkable,” Sasieni added.

This significant decline is likely a direct result of the HPV vaccine, with around 90% of women in the 20-24 age group in the UK vaccinated during their early teenage years. “This promising development underscores the vaccine’s lifesaving potential. It’s exciting to inform an entire generation that cervical cancer and several other types of cancer are no longer a risk for you,” stated Caroline Temmink, Director of Vaccination for the NHS.

While this investigation focuses on cervical cancer, the HPV vaccine also provides considerable benefits for other HPV-related cancers. Both genders can also prevent the formation of skin, genital, and anal warts through vaccination.

Notably, Sasieni and Falcaro also identified fatalities among women aged 25-29, but these numbers were significantly lower than what was projected. They estimate approximately 200 lives saved, a figure that represents just the beginning. “The 200 lives accounted for in our research is merely the surface; the protection seems to last long-term,” Sasieni explained. “In the future, we may estimate preventing around 18,000 deaths due to this vaccine.”

Nevertheless, HPV vaccination rates remain low globally, and cervical cancer incidence continues to rise. Alarmingly, recent data shows a decline in vaccination among teenagers in the UK since the COVID-19 pandemic. “The decline in vaccine uptake since COVID-19 is concerning,” Sasieni remarked.

“To eliminate cervical cancer by 2040, HPV vaccination must be combined with cervical cancer screening,” says Temmink. “This vaccine is safe and highly effective, and we strongly encourage all eligible individuals to take advantage of this opportunity when it arises.”